Podcast episode 37 (in German)
CJC-1295 with DAC: the long-acting signal for growth hormone
August 14, 2026
CJC-1295 with DAC turns a signal that would otherwise vanish within minutes into one that acts for days. The trick is a chemical anchor on the blood protein albumin, and the human data from clinical development are surprisingly good.
What it is about
CJC-1295 is a GHRH analog, an improved copy of the command with which the hypothalamus instructs the pituitary gland to release growth hormone. The version with DAC, the Drug Affinity Complex, carries a small maleimide anchor that binds firmly to albumin. The peptide thus rides piggyback and is protected from the enzymes that break down free peptides within minutes. The episode explains the technology, the clinical data, the debate about a continuous signal versus natural pulses and the difference from directly injected HGH. What remains is the most convenient peptide in the growth hormone series, which was never approved and is banned in sport.
Key points
- With DAC, the half-life rises to about 6 to 8 days; the body’s own GHRH does not survive 10 minutes, the version without DAC about half an hour.
- Teichman and colleagues showed in 2006 that a single injection increased growth hormone 2- to 10-fold for 6 days and longer, and IGF-1 1.5- to 3-fold for up to 11 days.
- Albumin, the most abundant protein in the blood, circulates for around 3 weeks; semaglutide with its fatty acid uses the same basic principle of an albumin anchor today.
- Development at ConjuChem was discontinued; an incident in a participant with a pre-existing condition at a very high dose prompted caution, and the connection remained unclear.
- The pituitary remains in charge: feedback via somatostatin curbs excesses, unlike injected HGH, which bypasses the body’s own axis and shuts down production.
- As a report: users describe deeper sleep, faster recovery and, over weeks, better skin and nails; effects on body fat and lean mass come gradually over months.
- The most common side effect is redness or wheals at the injection site; water retention, tingling in the hands, increased hunger and morning sluggishness are possible.
Where the data stop
The good human data come from a clinical development program that was discontinued; there is no approval, as of August 2026. What is sold today comes from the gray market, so a certificate of analysis is the minimum. The fundamental question is also open: whether a permanently raised baseline, the so-called GH bleed, achieves the same as the natural pulses is disputed. Some effects in muscle seem to depend on the peaks, and a continuous signal theoretically carries more risk of habituation.
As with anything that raises IGF-1, blood glucose needs to be watched. Anyone who has or has had active cancer has no business with growth signals. CJC-1295 is banned in sport. Anyone interested should have IGF-1 and fasting blood glucose measured beforehand and over time and discuss it with someone knowledgeable.
Listen (in German)
Listen on Spotify Listen on Apple Podcasts Listen on Amazon Music
Published on August 14, 2026.
The topic in the database
- The GHRH analog with a built-in long-acting anchor: the Drug Affinity Complex binds to albumin and extends the duration of action to 6–8 days – the most convenient growth…CJC-1295 with DAC
All episodes in the app (German)
Information only, not medical advice and not a usage or dosage recommendation. Prescription-only and unapproved substances belong in the hands of a physician. Last updated: 2026-10-09.